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Abstract The use of amniotic membrane (AM) is a
widespread clinical practice for eye surgeries and the
treatment of an increasing number of ocular surface
pathologies. Here we describe the AM collection
methods and donor selection criteria adopted by our
tissue bank to distribute 5349 amniotic membrane
patches over the last 12 years for the treatment of
several ocular pathologies. Specific quality control
measures are described and the long term results
attained using the reported procedure are presented. A
case of AM utilized to treat severe ocular ulceration is
also described as an example of AM transplantation.
Collective data for the total amniotic membrane
patches deployed to treat various ocular diseases are
discussed and success rates for AM transplantations
are reported. An extensive follow-up is illustrated. The
results suggest that the procedures and protocols used
by the Treviso Tissue Bank Foundation and Veneto
Eye Bank Foundation for collection, preservation,
distribution and follow-up are of an optimal standard.
Accordingly, the authors conclude that the safety and
efficiency of the proposed procedure for the therapeu-
tic use of AM to treat various ocular pathologies are
reproducible, with additional evidence favoring the
use of AM as an alternative to conventional medical
treatment for certain ocular conditions.
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Introduction
The amniotic membrane (AM) is the inner layer of the
fetal membranes and is comprised of three distinct
layers; epithelium, basementmembrane and stroma, the
innermost layer that further consists of an inner compact
layer, middle fibroblast layer and an outermost spongy
layer. The use of AM in patients was reported for the
treatment of cicatricial pemphigoid and Stevens–John-
son syndrome (Tsubota et al. 1996), pterygium (Prab-
hasawat et al. 1997), persistent epithelial defects with
ulceration (Lee and Tseng 1997), conjunctival surface
reconstruction (Tseng et al. 1997) and ocular surface
reconstruction in patients with chemical and thermal
burns (Shimazaki et al. 1997). The benefits of AM can
be attributed to its anti-inflammatory and anti-microbial
properties (Solomon et al. 2001) and low immuno-
genicity (Hori et al. 2006). The earliest evidence of its
low immunogenicity dates back to 1981, when Akle
et al. (1981) demonstrated the lack of immunogenicity
of human amniotic epithelial cells: in fact, these cells do
not express HLA-A, B, C, DR antigens or b2-
microglobulin on their surface. The basement
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membrane is involved in themigration of epithelial cells
(Terranova and Lyall 1986) and promotes their differ-
entiation (Guo and Grinnell 1989) and uniform strati-
fication. AM was also suggested as the ideal biological
substrate for limbal epithelial stem cells (Grueterich
et al. 2003); more specifically, AM prevents apoptosis,
promotes adhesion of various cells and helps maintain
normal epithelial cell morphology (Kurpakus et al.
1992; Ohno-Matsui et al. 2005). AM can be used as a
temporary graft and functions as a basement membrane
substitute in the eye; in fact, the presence of several
growth factors in the AM tissue, together with its
function as a structural support providing a basal
membrane for new cell growth, are believed to be the
main mechanisms by which the procedure achieves its
therapeutic effects. Another important property of AM
is its ability to inhibit vascularization. Hao et al. (2000)
identified several anti-angiogenic and anti-inflamma-
tory proteins in the AM. It is of note that the cornea and
vitreous are avascular tissues, which is why this
characteristic effect of AM is advantageous. Besides
the beneficial physical properties of AM, the possibility
of freezing and preserving AM patches has further
expanded their clinical utilization. AM treatment is
effective not only due to its clinical and pathological
properties, but also its availability and ease of collection
and preservation. Storage for months in tissue banks
offers sufficient time to plan and perform surgeries or
clinical trials (Dua and Azuara-Blanco 1999). Long
term and short term storage methods were previously
reported, including freeze-drying, storage inmedia up to
28 days (Hennerbichler et al. 2007). It was shown that
short term preservation can better conserve the cells
viability. At our tissue bank, AM patches are stored and
preserved at temperatures of below -140 C for up to
5 years. Many reports in the literature described the
storage ofAMat-80 Cand, depending onusage rates,
AM has been used up to 6 months (Madhavan et al.
2002) and even 1 year (Dekaris and Gabric´ 2009) after
preparation. Additionally, storage for an indefinite
period has also been suggested.
In this report, we describe pathological conditions
treated with human AM showing statistical data from
long term treatment. Transplantation of AM in an eye
with a chronic neurotrophic corneal ulceration is
presented as an example of the most frequent appli-
cation of AM in ophthalmology; corneal ulcers. To
manage the safety issues common to all transplanta-
tion procedures and provide a safe, sterile and
consistent product, the methods used for screening,
procurement, manipulation and banking AM tissue
must be carefully set up, standardized and validated.
The Tissue Bank Foundation of Treviso, in association
with the Veneto Eye Bank Foundation, has been
working on these methods for several years, refining
and optimizing operations. We now present our
experience in recovering and cryopreserving mem-
brane patches in compliance with strict specifications
designed to raise the standards and quality of the
membrane patches.
Materials and methods
Donor selection and screening
Donors were selected on the basis of strict criteria
including guidelines for harvesting, processing and
distributing tissues for transplantation as approved by
the National Transplant Centre. Selection criteria
include absence of history of malignancies, absence
of malformations or pathological conditions of the
baby, gestation period of at least 35 weeks, negative
medical history of the family for genetic diseases, and
lifestyles of both parents not at risk for infectious
diseases. The donor is also screened during pregnancy
for neurodegenerative diseases and acute infections.
The blood of the donors was also screened for HIV-1
and -2 antibodies, HTLV-1 and -2 antibodies, Hepati-
tis B Surface Antigen and Hepatitis B Core Antibody,
Hepatitis C virus (HCV) and syphilis. Screening also
included IgM/IgG antibodies against toxoplasmosis
and cytomegalovirus and nucleic acid amplification
tests (NAT) for HIV, HBV and HCV. A sample of the
donor’s serum was frozen and stored for further
investigation as required.
Isolation, preparation and cryopreservation
of amniotic membrane patches
The placenta was sourced from donors undergoing
caesarean sections and processed shortly after retrie-
val. The AM was carefully detached from the chorion
and rinsed with sterile saline solution to remove
residual blood. The membrane was flattened on a
nitrocellulose membrane filter (Merck Millipore),
with its stromal/mesenchymal side facing down, in
contact with the filter. The AM was immersed in a
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cocktail of antibiotics: vancomycin 50 lg/ml (Hos-
pira), polimyxin B 100 lg/ml (Biochrom), cef-
tazidime 240 lg/ml (Fresenius-Kabi), lincomycin
120 lg/ml at ?4 C for 24 h in sterile conditions.
Antibiotics are dissolved in RPMI 1640 Medium
without phenol-red (Gibco, Life technologies). The
AMwas then cut into pieces 3 9 3 cm2 and immersed
in 4 ml RPMI-1640 medium without phenol-red
(Gibco, Life technologies), supplemented with 10 %
human serum albumin and 10 % dimethyl sulfoxyde
(DMSO, Cryo Sure, WAK-Chemie Medical GmbH)
as cryopreservant. The patches were rolled up and
inserted into cryovials, which were then filled with the
cryopreservation medium/DMSO. Cryopreservation
was achieved using a programmable cryogenic freezer
(Planer KryoSave Integra, 750-30), which triggers a
controlled cooling rate, taking about an hour an half to
lower the temperature from ?4 C to -140 C. The
AM patches were stored in vapor-phase liquid nitro-
gen at -180 C.
Thawing and transportation
When required, cryovials containing the AM patches
were thawed in a water bath at 60 C, the nitrocellu-
lose filter papers were changed, and the AM patch was
repeatedly rinsed with sterile saline solution to wash
away the cryopreservation media. The membrane
patch was placed in a sealed container with 100 ml of
transport medium (RPMI 1640 without phenol-red),
which can be kept at 4 C for up to 72 h before
surgery. No antibiotics are added to the transport
media to avoid any adverse effect on the eye.
Microbiological analysis
In order to minimize the risk of contamination,
microbiological analyses were performed at several
stages throughout the process. Initial/primary pla-
centa, transport medium, rinsing medium, membrane
at the end of the process, medium at the end of the
process, cryopreservation medium, rinsing medium
after thawing, and transport medium from the tissue
bank to the surgery room, were all tested.
Distribution and patients
During the period 2003–2014, a total of 5604 mem-
brane patches were collected from 215 placentas; of
these, 5349 membranes were distributed to 220 centers
throughout Italy. Patients were enrolled after being
extensively informed about the treatment and giving
their written consent to the procedure, in compliance
with the Italian law. Various pathological conditions
were reported in terms of the class and severity of the
ocular defect. AM patches were supplied to all the
doctors who requested them and were provided
together with donor specifications and a questionnaire
for reporting adverse events.
Surgery and follow-up
Depending on the individual patient’s medical condi-
tion, surgeries included preliminary steps such as
cleansing, rinsing or removal of excessive tissue,
along with the preparation of the eye for AM
transplantation. Surgeries were performed under local
or peribulbar anesthesia. The AM was cut to the
required size and sutured to the ocular surface with the
epithelial surface facing upwards and the mesenchy-
mal side in direct contact with the eye to ensure secure
adhesion. For corneal ulceration the membrane was
positioned over the defect and sutured to the sur-
rounding cornea with 10/0 nylon sutures. This method
allows the membrane to cover the surface with
epithelial cells, which are then incorporated into the
corneal tissue (Lee and Tseng 1997). For deep ulcers, a
multilayer AM transplantation technique was adopted
(Kruse et al. 1999). In patients with deep ulcers and
herpetic keratitis (HK), epithelial debridement was
performed and loosely adherent epithelium was
removed before surgery. In band keratopathy a
superficial calcium deposit was removed before rins-
ing with 4 % EDTA solution. In patients with subtotal
stem cell deficiency associated with conjunctivaliza-
tion, a 2 mm retrocession was performed and the
fibrovascular pannus was removed by superficial
dissection. After positioning to cover the entire
corneal surface, the AM was sutured to the episclera.
Unlike the technique used for treating corneal ulcer-
ation, in this procedure the epithelium was allowed to
grow underneath the membrane. Conjunctival flaps
were placed above the membrane to avoid penetration
by fibrovascular tissue and to promote re-epithelial-
ization. A temporary tarsorrhaphy protected the AM in
these patients (Rama et al. 2001).
Post-surgery, patients were given 0.5 % cortisol for
1 week, together with fluoroquinolone (0.2 %
Cell Tissue Bank (2016) 17:51–58 53
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ciprofloxacin) four times a day. The regimen was then
reduced to decreasing cortisol doses for the following
3 weeks. Patient follow-up examinations were per-
formed 1, 3, 6 and 12 months after surgery. This
included an assessment of symptoms such as pain,
photophobia and inflammation. Intraocular pressure
and visual acuity were also measured, and re-epithe-
lialization was assessed by fluorescein staining. Stan-
dard photography and slit-lamp biomicroscopy were
used to evaluate corneal opacification and thickness.
Results
Distribution and pathological conditions treated
During the 12-year follow-up, 5604 amniotic mem-
branes were isolated from 215 placentas, of which 5192
membrane patches were used for transplantation, 342
were discarded and 70 were selected for research. The
recovery and banking procedure was successful in
almost all cases except when the patch was physically
damaged due to contact with vials during cryopreser-
vation. None of the distributed membranes were
positive for contamination after thawing, demonstrating
the reliability of themicrobiological controls performed
during tissue collection. Table 1 shows that 183 mem-
brane patches were discarded due to poor physical,
histological or morphological conditions before preser-
vation, 159 membrane patches were discarded after
delivery to hospital due to damage or specific surgical
reasons, and 70 membrane patches were selected for
research purposes. The data also show that the majority
of tissues collected were used for medical or surgical
procedures (92.65 %). As indicated in Table 1, out of
the total number of AM collected in the period, only
6.10 % were discarded due to physical damage after
preservation, low histological quality or by the surgeon,
while 1.25 % were used for research purposes. Table 2
includes a list of pathological conditions for which
surgeons used AM each year over a period of 12 years
between 2003 and September 2014. During this time a
total 5349 surgical procedures were successfully per-
formed using membrane patches distributed by the
tissue bank. Corneal ulceration accounted for almost
half of the cases (45.43 %). Other common conditions
treated with AMwere keratitis, endophthalmitis, chem-
ical trauma and neoplasm, among others. Details on the
use of AM for different pathological conditions are
reported in Table 2.
Postoperative follow-up
The clinical outcome for all cases was established with
1 year of postoperative follow-up. In general, success
was determined based on the scope of surgery and the
presence of one or a combination of the following
criteria: resolution of inflammation, relief of symptoms,
restoration of regular and stable corneal epithelium, and
restoration of the structural integrity of the eye.
Partial success was defined as attainment of only
two of the above criteria. Failure was defined as the
absence of all of the above criteria. Table 3 shows the
percentage of AM transplantation success, partial
success and failure.
Therapeutic effects after treatment were variable
and related to the type of pathological condition
treated. The best results were obtained when the
membrane was used to control inflammation and pain.
In general, a higher success rate was attained when
membrane transplantation was performed for its key
therapeutic indication, i.e. persistent epithelial defect
with stromal ulceration in patients with functional
limbal stem cell deficiency. In such cases the proce-
dure was able to promote re-epithelialization in the
majority of the patients and the restoration of a stable
Table 1 AM utilization percentages
Utilization 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014a Total
Grafted 345 384 426 453 437 467 489 533 475 458 429 296 5192
Sent then discarded 20 15 9 11 3 6 12 4 30 16 23 10 159
Discarded 11 18 9 4 7 17 5 11 12 9 15 65 183
Research 8 12 20 7 7 6 10 70
Total 384 429 464 475 454 490 506 548 523 493 467 371 5604
Number of AM used for transplantation, discarded or used for research between 2003 and 2014 (a up to 30/09/2014)
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corneal epithelium in ulcers caused by different
pathological conditions. In some patients, the AM
was successfully incorporated into the corneal tissue,
as demonstrated by the persistence of membrane
fragments that remained visible for several days after
surgery. In these cases, the membrane displayed its
‘scaffold-like’ properties by providing a healthy and
intact basal membrane on which the patient’s cells
were able to proliferate and restore the original
structure of the epithelium.
Amniotic membrane transplantation in ocular
ulcers
This report describes a successful AM transplantation
in a patient with frequently recurring HK over a period
of 3 years. The patient presented with a deep corneal
perforation caused by neurotrophic ulcers leading to
descemetocele formation (Fig. 1a). An inlay AM graft
was performed, as well as an outlay AM graft
(Fig. 1b). The gap was partially filled with cyanoacry-
late glue, which also served to keep the graft in
position. The graft assisted in preparing the patient for
PK, which was successfully performed (Fig. 1c).
Safety evaluation
No adverse reactions or other unexpected events
related to AM were reported by the surgeons. To date,
after a 12-year follow-up, the clinical history of AM
distributed for transplantation does not indicate any
harmful effects caused by AM, further confirming the
high safety margin assured by this therapy. Quality
controls include strict selection, analysis, processing
and distribution procedures to guarantee the safety of
the patches.
Table 2 Distribution and pathological conditions treated during the period 2003–2014
Pathological conditions 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014a Total
Corneal ulcers including
neurotrophic keratitis
142 160 182 199 179 219 256 235 240 244 214 160 2430
Keratitis/endophthalmitis 38 40 27 29 36 29 29 33 53 19 14 16 363
Pterygium 14 23 34 41 30 38 39 52 16 22 26 8 343
Post keratoplasty, glaucoma or
cataract
21 22 28 38 32 28 28 50 36 30 19 7 339
Chemical trauma 32 32 41 41 31 35 30 18 32 22 11 7 332
Bullous keratopathy 17 27 16 21 36 32 31 26 25 14 11 9 265
Neoplasm of the ocular surface 12 20 22 20 15 11 21 28 18 23 26 23 239
Reconstruction of the conjunctiva
and fornix
15 10 14 19 8 8 10 13 10 15 24 8 154
Corneal degeneration 5 7 11 4 3 11 8 12 15 11 21 15 123
Recurrent epithelial erosion 12 6 10 8 6 7 10 9 6 7 18 10 109
Primary and secondary limbal
stem cell deficiency
9 10 12 6 3 4 5 13 11 5 78
Mucous membrane pemphigoid 9 5 4 4 3 6 6 5 4 7 4 2 59
Dystrophy 5 8 3 2 5 9 2 10 4 2 1 7 58
Mechanical trauma 1 3 1 6 3 5 3 1 2 25
Stevens–Johnson or Lyell’s
syndrome
3 1 1 1 4 7 3 20
Reconstruction of the
anophthalmic cavity
1 2 1 3 3 2 3 1 1 17
Physical trauma 3 3 2 1 5 1 1 16
Eyelid reconstruction 2 1 1 1 3 3 11
Dysfunctional tear syndrome 1 1 3 1 1 2 9
Other 29 23 24 26 44 35 22 33 30 30 41 22 359
Data on the number of AM utilized for ocular conditions between 2003 and 2014 (aup to 30/09/2014)
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Discussion
The purpose of the present study is to evaluate the role
of human AM in the treatment of various conditions,
in particular epithelial ulceration, pterygium, keratitis,
glaucoma, bullous keratopathy (see Table 2). The
benefits and safety features of AM in ocular disorders
are evident, based on long term data analysis of these
procedures. Also, as for the 12-year data and follow-
up, our selection, isolation, pathological analysis,
Table 3 Success rates for AM therapy
Pathological condition Success (%) Partial success (%) Failure (%)
Corneal ulcers including neurotrophic keratitis 100
Keratitis/endophthalmitis 90 10
Pterygium 71 21 8
Post keratoplasty, glaucoma or cataract 100
Chemical trauma 15 61 24
Bullous keratopathy 100
Neoplasia of the ocular surface 50 17 33
Reconstruction of the conjunctiva and fornix 30 23 47
Corneal degeneration 100
Recurrent epithelial erosions 85 10 5
Primary and secondary limbal stem cell deficiency 18 50 32
Mucous membrane pemphigoid 10 11 79
Dystrophy 100
Mechanical trauma 100
Stevens–Johnson or Lyell’s syndrome 19 19 62
Reconstruction of the anophthalmic cavity 100
Physical trauma 70 30
Eyelid reconstruction 100
Dysfunctional tear syndrome 100
Other 29 17 54
Data on success rates for AM ocular therapies between 2003 and 2014
Fig. 1 Treatment of corneal ulceration using AM. A patient
with descemetocele white arrow caused by recurring HK (a).
AM transplantation was performed and the gap was filled with
membrane and glue (b). Images taken few weeks after filling
and grafting. After AM grafting, penetrating keratoplasty was
performed (c)
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distribution and post-operative protocols were found
to adhere to high standards, as reflected by the success
rates for various procedures and surgeries. In the past,
conjunctival autografts have been used with good
clinical outcomes, but this procedure cannot be used in
ocular cicatricial pemphigoid or Stevens–Johnson
syndrome (bilateral diseases). The ocular surface is
an extremely sensitive structure, whose health is
crucial for the optimal functioning of the eye. The use
of AM appears to be a useful alternative in the
treatment of ocular surface disorders. AM has many
important properties, including as an anti-fibrotic and
anti-inflammatory agent. Fetal hyaluronic acid has
been reported to suppress TGFb signaling, which in
turn inhibits the proliferation of conjunctival, corneal
and limbal fibroblasts (Hao et al. 2000; Lee et al. 2000).
In addition, AM has anti-angiogenic properties deriv-
ing from the production of several potent anti-angio-
genic chemicals including thrombospondin-1,
endostatin and all four tissue metalloproteinase
inhibitors (Hao et al. 2000). The anti-microbial prop-
erties of AM have also been reported, with evidence of
activity against both gram negative bacilli (Kjaergaard
et al. 2001) and gram positive cocci (Kjaergaard et al.
1999). Beside its use in ophthalmology, AM has many
applications in a range of medical conditions and
procedures, such as diabetic foot ulcer grafts (Zelen
et al. 2013), chronic burn wound dressings (Moham-
madi et al. 2013), vaginoplasty (Fotopoulou et al.
2010) and myelomeningocele repair (Hasegawa et al.
2004). The ability of AM to promote healing of the
epitheliummay derive from the basement membrane’s
tendency to facilitate the migration of epithelial cells,
promote epithelial differentiation and reduce inflam-
mation, scarring and vascularization. Based on the
large number of cases reported here, the safety and
effectiveness of AM transplantation for common
ocular surface conditions can be demonstrated. AM
may also represent a viable therapeutic alternative
when conservative medical treatment fails. In partic-
ular, corneal ulceration is the most frequent condition
treated byAM transplantation (45.43 %),with a 100 %
success rate in 2430 patients, further highlighting the
important role of AM in the treatment of ocular
diseases. Lee and Tseng (1997) performed AM trans-
plantation in 11 eyes of 11 consecutive patients with
corneal ulcers; the corneal epithelial defects had
persisted for a mean of 17.5 ± 13.9 weeks. Another
report on the clinical use of AM in the treatment of
corneal ulcers is by Kruse et al. (1999), who reported
on the use of multiple layers of AM to reconstruct deep
corneal ulcers in 11 patients; after a 1-year follow-up
the defects had healed in 9 out of 11 patients (Kruse
et al. 1999). In the case of keratitis (6.79 % of total
cases), a success rate of 90 % was recorded; for
pterygium (6.41 %), the success ratewas 71 %; and for
the treatment of surgical outcomes (6.34 %), the
success rate was 100 %. The average success rate for
all conditions was 69.25 %, however, for 10 conditions
treated with AM the success rate was more than 90 %.
This excellent feedback data can be credited to the
properties of AMand probably also to the presence of a
fraction of viable cells in cryopreserved AM prepara-
tions (Hennerbichler et al. 2007). However, it seems
that the integrity of the matrix is more significant than
the viability of the epithelium with regard to the
biological properties of the membrane. Several AM
denudation methods failed to prevent the growth of
limbal stem cells, as recently reported (Zhang et al.
2013). Unlike other procedures by tissue banks (Dua
and Azuara-Blanco 1999), our procedure contains a
washing step prior to use of the AM. Although this can
wash away many biologically active molecules, it is
believed to be an important step for washing away
DMSO and preservation media. AM can be preserved
for a longer time and retains its activity when stored at
4 C for up to 72 h, allowing for correct membrane
preparation and transportation to institutions or hospi-
tals, and providing sufficient time for preoperative
planning. The success of the re-epithelialization pro-
cess depends on the release of plentiful growth factors
by a healthy population of AM cells. Less satisfactory
results can be seen when AM transplantation is used to
treat patients with severe limbal stem cell deficiency.
In such cases the procedure is unsuccessful in promot-
ing the regeneration of the epithelial layer, probably
due to extensive damage to stem cells in the limbal
region and their inability to repeatedly proliferate. For
these patients, the treatment did provide some degree
of relief from pain and inflammation, which was also
useful as a preliminary step prior to limbal transplan-
tation surgery.
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